Ambrx Articles
Bristol-Myers gets added indication from US FDA for Sustiva; signs second deal with Ambrx
6 May 2013
Astellas and Ambrx collaborate in up to $300 oncology deal; Teijin takes stake in Kyorin
5 April 2013
Ambrx signs up to $300 million deal with Merck & Co
19 June 2012
Bristol-Myers teams up with Ambrx for novel biologics programs in diabetes and heart failure
23 September 2011
Showing 1-4 of 4 articles
- 1
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- New study shows UCB's Neupro reduces NSBP in RLS patient
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
